Evolution Advisers’s Pfizer PFE Stock Holding History

Evolution Advisers’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+7	New	+$183	﹤0.01%	705
2025 Q1	–	Sell	-48	Closed	-$1K	–	173
2024 Q4	$1K	Buy	+48	New	+$1.3K	﹤0.01%	151
2023 Q4	–	Sell	-794	Closed	-$26K	–	226
2023 Q3	$26K	Hold	794	–	–	0.02%	90
2023 Q2	$29K	Hold	794	–	–	0.02%	87
2023 Q1	$32K	Hold	794	–	–	0.02%	76
2022 Q4	$40K	Hold	794	–	–	0.03%	70
2022 Q3	$34K	Hold	794	–	–	0.03%	69
2022 Q2	$41K	Hold	794	–	–	0.03%	65
2022 Q1	$41K	Buy	794 +600	+309%	+$31.1K	0.03%	69
2021 Q4	$11K	Buy	+194	New	+$9.61K	0.01%	93

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Evolution Advisers's PFE Position: Q2 2026 in Review

Evolution Advisers opened a new position in Pfizer (PFE) in Q2 2026: 7 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #705 among its holdings. This is a return to the name: Evolution Advisers previously reported a position in PFE as recently as Q4 2024.

Evolution Advisers first reported a position in PFE in Q4 2021 and has held it in 10 quarters since. The position peaked at $41K in Q2 2022. 2,834 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Evolution Advisers held 7 shares of Pfizer worth $0 as of Q2 2026.
Pfizer was a new Evolution Advisers position in Q2 2026.
Pfizer made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #705 holding.
Evolution Advisers first reported a position in Pfizer in Q4 2021 and has held it in 10 quarters since.
Evolution Advisers's Pfizer position peaked at $41K in Q2 2022.
2,834 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.